| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.2 | 0.2 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.21 | 0.2 |